Published in Am J Psychiatry on March 01, 2004
Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol (2009) 11.59
Electroconvulsive therapy stimulus parameters: rethinking dosage. J ECT (2010) 1.01
Quick recovery of orientation after magnetic seizure therapy for major depressive disorder. Br J Psychiatry (2008) 1.00
Brain stimulation in posttraumatic stress disorder. Eur J Psychotraumatol (2011) 0.98
Brain stimulation in psychiatry and its effects on cognition. Nat Rev Neurol (2010) 0.98
Hippocampal neurogenesis and antidepressive therapy: shocking relations. Neural Plast (2014) 0.91
Applications of transcranial magnetic stimulation and magnetic seizure therapy in the study and treatment of disorders related to cerebral aging. Dialogues Clin Neurosci (2013) 0.90
Unaltered neuronal and glial counts in animal models of magnetic seizure therapy and electroconvulsive therapy. Neuroscience (2009) 0.86
Translational development strategy for magnetic seizure therapy. Exp Neurol (2009) 0.85
Somatic treatments for mood disorders. Neuropsychopharmacology (2011) 0.82
Magnetic Seizure Therapy for Unipolar and Bipolar Depression: A Systematic Review. Neural Plast (2015) 0.80
A systematic review of the neurocognitive effects of magnetic seizure therapy. Int Rev Psychiatry (2011) 0.79
Multifactorial determinants of the neurocognitive effects of electroconvulsive therapy. J ECT (2014) 0.78
Electro-convulsive Therapy: A Few Lingering Thoughts/Doubts! Indian J Psychol Med (2011) 0.75
Astrocytic activation as evidence for brain damage. Am J Psychiatry (2005) 0.75
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry (2006) 12.41
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials (2004) 6.64
Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry (2007) 5.59
Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am (2003) 5.05
Using the gene ontology for microarray data mining: a comparison of methods and application to age effects in human prefrontal cortex. Neurochem Res (2004) 4.33
Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Am J Psychiatry (2004) 3.84
Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology (2006) 3.80
Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. Brain Stimul (2008) 3.50
Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry (2010) 3.14
Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron (2002) 3.06
Electric field depth-focality tradeoff in transcranial magnetic stimulation: simulation comparison of 50 coil designs. Brain Stimul (2012) 2.92
Lateral prefrontal cortex and self-control in intertemporal choice. Nat Neurosci (2010) 2.88
Parietal cortex and representation of the mental Self. Proc Natl Acad Sci U S A (2004) 2.73
Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology (2009) 2.63
Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science (2006) 2.49
Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology (2008) 2.31
Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. Am J Psychiatry (2006) 2.31
Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry (2005) 2.24
Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry (2004) 2.24
Response inhibition predicts poor antidepressant treatment response in very old depressed patients. Am J Geriatr Psychiatry (2007) 2.18
Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. Biol Psychiatry (2005) 2.16
Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates. J Neurosci (2007) 2.12
Association of life activities with cerebral blood flow in Alzheimer disease: implications for the cognitive reserve hypothesis. Arch Neurol (2003) 2.08
Molecular aging in human prefrontal cortex is selective and continuous throughout adult life. Biol Psychiatry (2005) 2.06
Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry (2005) 2.03
Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry (2006) 1.96
Adequacy of antidepressant treatment after discharge and the occurrence of suicidal acts in major depression: a prospective study. Am J Psychiatry (2002) 1.95
Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. Biol Psychiatry (2003) 1.94
Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry (2012) 1.91
Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry (2005) 1.90
Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. J Clin Psychiatry (2006) 1.90
Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry (2008) 1.89
Volumetric analysis of the prefrontal cortex, amygdala, and hippocampus in major depression. Neuropsychopharmacology (2004) 1.82
Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J Neurosci (2008) 1.80
A new approach to spatial covariance modeling of functional brain imaging data: ordinal trend analysis. Neural Comput (2005) 1.78
Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression. Am J Geriatr Psychiatry (2007) 1.76
Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635. Brain Res (2002) 1.71
Vascular depression: A distinct diagnostic subtype? Biol Psychiatry (2006) 1.66
Pharmacological strategies in the prevention of relapse after electroconvulsive therapy. J ECT (2013) 1.62
Cognitive reserve modulates functional brain responses during memory tasks: a PET study in healthy young and elderly subjects. Neuroimage (2003) 1.62
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS (2011) 1.62
Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res (2008) 1.61
Clinical outcome of ECT in patients with major depression and comorbid borderline personality disorder. Am J Psychiatry (2004) 1.59
Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry (2005) 1.57
Regional heterogeneity of 5-HT1A receptors in human cerebellum as assessed by positron emission tomography. J Cereb Blood Flow Metab (2005) 1.55
Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. Int J Neuropsychopharmacol (2002) 1.51
A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry (2005) 1.48
Fundamentals of transcranial electric and magnetic stimulation dose: definition, selection, and reporting practices. Brain Stimul (2011) 1.45
Necessity of hippocampal neurogenesis for the therapeutic action of antidepressants in adult nonhuman primates. PLoS One (2011) 1.45
The efficacy of acute electroconvulsive therapy in atypical depression. J Clin Psychiatry (2008) 1.44
Serotonin-1A autoreceptor binding in the dorsal raphe nucleus of depressed suicides. J Psychiatr Res (2007) 1.40
Correlates of trait impulsiveness in performance measures and neuropsychological tests. Psychiatry Res (2005) 1.36
Sex genes for genomic analysis in human brain: internal controls for comparison of probe level data extraction. BMC Bioinformatics (2003) 1.36
Attenuated 5-HT1A receptor signaling in brains of suicide victims: involvement of adenylyl cyclase, phosphatidylinositol 3-kinase, Akt and mitogen-activated protein kinase. J Neurochem (2003) 1.36
Neuronal tryptophan hydroxylase mRNA expression in the human dorsal and median raphe nuclei: major depression and suicide. Neuropsychopharmacology (2006) 1.35
Gene expression profiling of depression and suicide in human prefrontal cortex. Neuropsychopharmacology (2004) 1.33
Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy. Neuropsychopharmacology (2003) 1.30
Hippocampal angiogenesis and progenitor cell proliferation are increased with antidepressant use in major depression. Biol Psychiatry (2012) 1.25
Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography. Arch Gen Psychiatry (2007) 1.25
Enhancement of human cognitive performance using transcranial magnetic stimulation (TMS). Neuroimage (2013) 1.25
Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS). Int J Neuropsychopharmacol (2005) 1.22
Transcranial magnetic stimulation: a neuroscientific probe of cortical function in schizophrenia. Biol Psychiatry (2011) 1.22
More tryptophan hydroxylase in the brainstem dorsal raphe nucleus in depressed suicides. Brain Res (2005) 1.22
Neocortical and hippocampal neuron and glial cell numbers in the rhesus monkey. Anat Rec (Hoboken) (2007) 1.21
A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. J Clin Psychiatry (2003) 1.21
Abnormalities of SNARE mechanism proteins in anterior frontal cortex in severe mental illness. Cereb Cortex (2002) 1.18
Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol Psychiatry (2002) 1.17
Electroconvulsive therapy and repetitive transcranial magnetic stimulation in children and adolescents: a review and report of two cases of epilepsia partialis continua. Child Adolesc Psychiatr Clin N Am (2005) 1.17
Hippocampal granule neuron number and dentate gyrus volume in antidepressant-treated and untreated major depression. Neuropsychopharmacology (2013) 1.16
Human 5-HT1A receptor C(-1019)G polymorphism and psychopathology. Int J Neuropsychopharmacol (2004) 1.16
Focal electrical stimulation as a sham control for repetitive transcranial magnetic stimulation: Does it truly mimic the cutaneous sensation and pain of active prefrontal repetitive transcranial magnetic stimulation? Brain Stimul (2008) 1.13
Magnetic seizure therapy improves mood in refractory major depression. Neuropsychopharmacology (2003) 1.13
A magnetic resonance spectroscopic imaging study of adult nonhuman primates exposed to early-life stressors. Biol Psychiatry (2003) 1.10
Direct injection of noise to the visual cortex decreases accuracy but increases decision confidence. J Neurophysiol (2011) 1.09
Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry (2015) 1.09
Randomized controlled trial of the cognitive side-effects of magnetic seizure therapy (MST) and electroconvulsive shock (ECS). Int J Neuropsychopharmacol (2005) 1.08
Evidence for impaired cortical inhibition in patients with unipolar major depression. Biol Psychiatry (2005) 1.08
Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry (2005) 1.07
Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimul (2010) 1.07
Brief pulse and ultrabrief pulse right unilateral electroconvulsive therapy (ECT) for major depression: efficacy, effectiveness, and cognitive effects. J Clin Psychiatry (2014) 1.06
Neurophysiological characterization of magnetic seizure therapy (MST) in non-human primates. Suppl Clin Neurophysiol (2003) 1.05
Cognitive reserve-mediated modulation of positron emission tomographic activations during memory tasks in Alzheimer disease. Arch Neurol (2004) 1.05
Review of fluorescent standards for calibration of in situ fluorometers: recommendations applied in coastal and ocean observing programs. Opt Express (2011) 1.05
A transcranial magnetic stimulator inducing near-rectangular pulses with controllable pulse width (cTMS). IEEE Trans Biomed Eng (2008) 1.05
Randomized sham-controlled trial of repetitive transcranial magnetic stimulation in treatment-resistant obsessive-compulsive disorder. Int J Neuropsychopharmacol (2009) 1.05
Deep brain stimulation in movement and psychiatric disorders. Biol Psychiatry (2006) 1.05
Mitochondrial abnormalities in temporal lobe of autistic brain. Neurobiol Dis (2013) 1.04
Genome-wide divergence of DNA methylation marks in cerebral and cerebellar cortices. PLoS One (2010) 1.03